Anzeige
Meldung des Tages: Dieses 4-Millionen-Dollar-Unternehmen will jetzt im August den Uran-Jackpot anbohren!

Sanofi

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
73,49 €
+0,44 €
+0,60%
17:46:31 Uhr
Depot/Watchlist
Marktkapitalisierung *
91,57 Mrd. €
Streubesitz
47,89%
KGV
12,98
Dividende
3,92 EUR
Dividendenrendite
5,29%
Nachhaltigkeits-Score
69 %
Index-Zuordnung
Euro Stoxx 50
Weiter aufwärts? Long handeln - Jetzt mit Hebel 9,75: MK76DN
Werbung
Warnung
Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlage­strategien geeignet.

Ad-hocs

07:15 Uhr - GlobeNewswire
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-​immune modulation to help address the underlying causes ...
07:00 Uhr - GlobeNewswire
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-​targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a ...
22.06.26 - GlobeNewswire
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi a ppoints Paulo Fontoura as Global  Head of  R&D
19.06.26 - GlobeNewswire
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
13.06.26 - GlobeNewswire
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi’s Tzield approved in the US as the first disease-​modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
10.06.26 - GlobeNewswire
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
08.06.26 - GlobeNewswire
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sarclisa administered via the CirCLIQ ® OBI offers a ...
04.06.26 - GlobeNewswire
Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches 2026 global employee stock purchase plan
28.05.26 - GlobeNewswire
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026 . The US Food and Drug Administration (FDA) has granted priority review ...
18.05.26 - GlobeNewswire
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD  
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-​of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-​to-head ...
29.04.26 - GlobeNewswire
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Annual General Meeting of April 29, 2026
24.04.26 - GlobeNewswire
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue
23.04.26 - GlobeNewswire
Press Release: Q1 2026: double-digit sales and business EPS growth
Q1 2026: double-​digit sales and business EPS growth
22.04.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
22.04.26 - GlobeNewswire
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to ...
22.04.26 - GlobeNewswire
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to ...
18.04.26 - GlobeNewswire
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-​to-head study First head-​to-head, double-​blind, randomized phase 4 study ...
13.04.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
31.03.26 - GlobeNewswire
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
Sanofi’s Rezurock approved in the EU to treat chronic graft-​vs-host disease
28.03.26 - GlobeNewswire
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-​breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 ...

Newssuche

Videos

newspaper
11.06.26 +20,00%
Technical Trading: Erdgas Short mit 75% Treffern
Erdgas Short Typ: Turbo Open End WKN: VJ5JDB Hebel: 4,66 Laufzeit: OpenEnd Einstieg: Market ... Mehr »